601607 上海医药
已收盘 12-05 15:00:00
资讯
新帖
简况
历时4年终无果 上海医药终止与生诺生物合作协议
财中社 · 12-05 16:52
历时4年终无果 上海医药终止与生诺生物合作协议
上海医药(601607.SH)：米诺地尔搽剂获得批准生产
智通财经网 · 12-05 16:05
上海医药(601607.SH)：米诺地尔搽剂获得批准生产
每周股票复盘：上海医药（601607）拟取消监事会并修订章程
证券之星 · 11-23
每周股票复盘：上海医药（601607）拟取消监事会并修订章程
监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成
华夏时报网 · 11-22
监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成
上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%
证券之星 · 11-18
上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%
上海医药(02607)将派发中期股息每10股1.2元
智通财经 · 11-18
上海医药(02607)将派发中期股息每10股1.2元
每周股票复盘：上海医药（601607）两抗生素药通过一致性评价
证券之星 · 11-16
每周股票复盘：上海医药（601607）两抗生素药通过一致性评价
上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%
证券之星 · 11-11
上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%
上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价
智通财经 · 11-10
上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价
【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）
证券之星 · 11-07
【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）
股市必读：上海医药（601607）11月6日披露最新机构调研信息
证券之星 · 11-07
股市必读：上海医药（601607）11月6日披露最新机构调研信息
上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与
证券之星 · 11-06
上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与
上海医药(601607.SH)：枸橼酸托法替布缓释片获得批准生产
智通财经 · 11-06
上海医药(601607.SH)：枸橼酸托法替布缓释片获得批准生产
上海医药(601607.SH)：替格瑞洛片获得美国FDA批准文号
智通财经 · 11-06
上海医药(601607.SH)：替格瑞洛片获得美国FDA批准文号
瑞银：升上海医药(02607)目标价至15港元 评级“买入”
智通财经 · 11-03
瑞银：升上海医药(02607)目标价至15港元 评级“买入”
每周股票复盘：上海医药（601607）Q3净利降38.13%，拟每10股派1.2元
证券之星 · 11-02
每周股票复盘：上海医药（601607）Q3净利降38.13%，拟每10股派1.2元
港股异动 | 上海医药(02607)跌超5% 计提资产减值准备增加 三季度纯利同比下降38.13%
智通财经 · 10-31
港股异动 | 上海医药(02607)跌超5% 计提资产减值准备增加 三季度纯利同比下降38.13%
图解上海医药三季报：第三季度单季净利润同比下降38.13%
证券之星 · 10-30
图解上海医药三季报：第三季度单季净利润同比下降38.13%
上海医药拟每10股派发现金红利1.2元
财中社 · 10-30
上海医药拟每10股派发现金红利1.2元
上海医药(601607.SH)：溴吡斯的明缓释片获得批准生产
智通财经 · 10-28
上海医药(601607.SH)：溴吡斯的明缓释片获得批准生产
加载更多
公司概况
公司名称：
上海医药集团股份有限公司
所属行业：
零售业
上市日期：
1994-03-24
主营业务：
上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。
发行价格：
4.50
{"stockData":{"symbol":"601607","market":"SH","secType":"STK","nameCN":"上海医药","latestPrice":17.9,"timestamp":1764918001000,"preClose":17.89,"halted":0,"volume":10972376,"delay":0,"changeRate":0.0006,"floatShares":2789000000,"shares":3708000000,"eps":1.5224,"marketStatus":"已收盘","change":0.01,"latestTime":"12-05 15:00:00","open":17.88,"high":17.9,"low":17.77,"amount":196000000,"amplitude":0.0073,"askPrice":17.9,"askSize":918,"bidPrice":17.89,"bidSize":285,"shortable":0,"etf":0,"ttmEps":1.5224,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":17.89,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":19.68,"lowLimit":16.1,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":3708361809,"isCdr":false,"pbRate":0.88,"roa":"--","peRate":11.757751,"roe":"6.96%","epsLYR":1.23,"committee":0.027612,"marketValue":66380000000,"turnoverRate":0.0039,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-12-08。","hkstockBrief":{"symbol":"02607","market":"HK","secType":"STK","nameCN":"上海医药","latestPrice":12.16,"timestamp":1764922148006,"preClose":12.07,"halted":0,"volume":4514841,"delay":0,"premium":"-38.32"},"floatMarketCap":49927000000},"requestUrl":"/m/hq/s/601607","defaultTab":"news","newsList":[{"id":"2589860452","title":"历时4年终无果 上海医药终止与生诺生物合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2589860452","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589860452?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:52","pubTimestamp":1764924759,"startTime":"0","endTime":"0","summary":"12月5日，上海医药（601607/02607）发布公告，宣布与贵州生诺生物科技有限公司的合作协议终止。该协议于2021年10月8日签署，涉及新型抑酸剂X842项目，允许公司全资子公司上药信谊获得该项目的独家生产和销售权。基于对外部市场的综合评估及各方经营发展规划的考虑，2025年11月18日，上药信谊与生诺生物达成了终止协议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512053583869660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","601607","BK0209","BK1197","BK0012","BK0175","BK0196","BK0097","BK0028","BK0184","02607","BK0099","BK0187","BK0188","BK0020"],"gpt_icon":0},{"id":"2589862429","title":"上海医药(601607.SH)：米诺地尔搽剂获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2589862429","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589862429?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:05","pubTimestamp":1764921958,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上药东英(江苏)药业有限公司的米诺地尔搽剂收到国家药品监督管理局颁发的《药品注册证书》，该药品获得批准生产。米诺地尔搽剂最早由强生公司开发，2%规格于1988年在美国上市，5%规格于1997年在美国上市。2024年1月，上药东英就该药品向国家药监局提出注册申请并获受理。截至公告日，公司针对该药品已投入的研发费用约人民币656万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1197","BK0196","BK0097","601607","BK0012","BK0183","BK0184","BK0187","BK0188","BK0028","BK0209","BK0099","BK0175","02607","BK0020"],"gpt_icon":0},{"id":"2585811103","title":"每周股票复盘：上海医药（601607）拟取消监事会并修订章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2585811103","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585811103?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:05","pubTimestamp":1763834714,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，上海医药报收于17.72元，较上周的18.32元下跌3.28%。本周关注点公司公告汇总：上海医药拟取消监事会，由董事会审计委员会行使监事会职权，并修订《公司章程》。上海医药集团股份有限公司将于2025年12月9日召开2025年第二次临时股东大会，会议采用现场投票与网络投票相结合的方式。其中，取消监事会并修订《公司章程》为特别决议议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK0020","BK0097","BK0188","BK0209","BK0184","601607","BK0012","BK1197","BK0175","BK0028","BK0196","BK0183","02607","BK0187"],"gpt_icon":0},{"id":"2585173352","title":"监事会竟被“一键删除”！上海医药屡犯合规问题，扣非净利下滑超两成","url":"https://stock-news.laohu8.com/highlight/detail?id=2585173352","media":"华夏时报网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585173352?lang=zh_cn&edition=full","pubTime":"2025-11-22 12:24","pubTimestamp":1763785443,"startTime":"0","endTime":"0","summary":"近年来，上海医药的整体发展节奏逐渐放缓，曾经稳健的增长态势面临新的压力。作为工商一体型药企，其核心的工业板块遭遇经营瓶颈，商业板块与工业创新之间的资源分配矛盾日益凸显，如何在短期盈利目标与长期创新战略间找到平衡，成为公司转型路上亟待破解的难题。更值得警惕的是，公司在合规管理层面的漏洞不断显现，旗下子公司因违规行为受到处罚，反映出集团对子公司的监管体系存在明显短板。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511223572004263.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511223572004263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","BK0099","BK0183","BK0175","BK0020","BK0012","BK0187","BK1197","BK0097","BK0209","601607","BK0028","BK0184","02607","BK0196"],"gpt_icon":0},{"id":"2584495343","title":"上海医药（601607）披露拟取消监事会并修订公司章程，11月18日股价下跌0.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584495343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584495343?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:13","pubTimestamp":1763475199,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，上海医药报收于17.99元，较前一交易日下跌0.61%，最新总市值为667.13亿元。该股当日开盘18.08元，最高18.16元，最低17.94元，成交额达2.2亿元，换手率为0.44%。近日，上海医药集团股份有限公司发布公告称，公司拟取消监事会，由董事会审计委员会行使监事会职权，并修订《公司章程》及附件《股东大会议事规则》《董事会议事规则》，同时废止《监事会议事规则》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0020","BK0097","BK0187","BK0188","BK0196","BK1197","02607","BK0099","BK0184","BK0175","BK0012","601607","BK0028","BK0209"],"gpt_icon":0},{"id":"2584987599","title":"上海医药(02607)将派发中期股息每10股1.2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584987599","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584987599?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:49","pubTimestamp":1763455795,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，将派发截至2025年6月30日止6个月的中期股息每10股1.2元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0187","BK1197","BK0020","BK0028","BK0196","BK0099","02607","BK0012","BK0175","BK0209","BK0184","BK0188","BK0097","601607"],"gpt_icon":0},{"id":"2583065619","title":"每周股票复盘：上海医药（601607）两抗生素药通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2583065619","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583065619?lang=zh_cn&edition=full","pubTime":"2025-11-16 01:23","pubTimestamp":1763227389,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，上海医药报收于18.32元，较上周的17.96元上涨2.0%。本周关注点公司公告汇总：注射用头孢呋辛钠及氨曲南通过仿制药一致性评价公司公告汇总：醋酸艾司利卡西平片获美国FDA最终批准上市公司公告汇总上海医药集团股份有限公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠和注射用氨曲南收到国家药监局颁发的《药品补充申请批准通知书》，通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK1197","BK0184","BK0028","BK0187","BK0196","BK0099","BK0209","BK0183","BK0020","BK0097","BK0188","02607","BK0175","601607"],"gpt_icon":0},{"id":"2582541913","title":"上海医药（601607）披露醋酸艾司利卡西平片获得美国FDA批准文号，11月11日股价上涨0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582541913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582541913?lang=zh_cn&edition=full","pubTime":"2025-11-11 17:23","pubTimestamp":1762852983,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，上海医药报收于18.37元，较前一交易日上涨0.55%，最新总市值为681.23亿元。近日，上海医药集团股份有限公司发布公告称，公司下属上海上药中西制药有限公司收到美国FDA通知，其申报的醋酸艾司利卡西平片简略新药申请已获得最终批准上市。该药品用于治疗4岁及以上患者的癫痫部分性发作，最早于2013年在美国上市。目前该药品在美国已有多个仿制药上市，2024年美国市场销售额约为3.82亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111100027989.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK0012","BK0099","BK0196","601607","BK0175","BK0097","BK0209","BK0028","BK0187","BK0183","BK1197","BK0184","BK0188","BK0020"],"gpt_icon":0},{"id":"2582407608","title":"上海医药(601607.SH)：注射用头孢呋辛钠及注射用氨曲南通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2582407608","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582407608?lang=zh_cn&edition=full","pubTime":"2025-11-10 15:38","pubTimestamp":1762760292,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药 发布公告，近日，公司下属上海上药新亚药业有限公司的注射用头孢呋辛钠、注射用氨曲南收到国家药品监督管理局颁发的《药品补充申请批准通知书》，前述药品通过仿制药质量和疗效一致性评价。注射用氨曲南适用于治疗敏感革兰氏阴性菌引起的感染：尿路、下呼吸道感染、败血症、皮肤和皮肤结构感染、腹腔内感染和妇科感染。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0175","BK0187","02607","BK0209","BK0196","BK1197","BK0028","BK0183","BK0020","BK0099","BK0188","BK0012","BK0097","BK0184","601607"],"gpt_icon":0},{"id":"2581042070","title":"【机构调研记录】中信建投调研精智达、上海医药等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2581042070","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581042070?lang=zh_cn&edition=full","pubTime":"2025-11-07 08:04","pubTimestamp":1762473894,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及11月6日披露的机构调研信息，中信建投近期对5家上市公司进行了调研，相关名单如下：1）精智达 调研纪要：2025年前三季度，公司实现营业收入75,304.00万元，同比增长33.00%。4）海新能科 调研纪要：公司前三季度业绩实现扭亏为盈。前三季度毛利率下滑主因低毛利的智能售货系统收入增长。旗下最近一年表现最佳的公募基金产品为中信建投悦享6个月持有期债券C，最新单位净值为2.74，近一年增长148.33%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700005589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0276","BK1197","BK0196","BK0028","688627","601066","BK0251","BK0187","BK0184","BK0099","BK0175","02607","601607","BK0012","BK0097","BK0020","BK0209","BK0188"],"gpt_icon":0},{"id":"2581742015","title":"股市必读：上海医药（601607）11月6日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2581742015","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581742015?lang=zh_cn&edition=full","pubTime":"2025-11-07 01:45","pubTimestamp":1762451119,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，上海医药报收于17.86元，上涨0.0%，换手率0.38%，成交量10.54万手，成交额1.88亿元。来自公司公告汇总：上海医药拟取消监事会，由董事会审计委员会行使监事会职权，相关议案尚需股东大会审议。下属企业上海上药中西制药有限公司的枸橼酸托法替布缓释片获国家药监局批准生产，注册分类为化学药品4类，用于类风湿关节炎、银屑病关节炎和强直性脊柱炎，2024年中国大陆医院采购金额为5404.99万元，累计研发投入约1941.92万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700001090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0099","BK0028","BK0012","BK0097","BK0196","BK0209","BK1197","BK0184","601607","BK0188","BK0183","BK0187","BK0175","02607","BK0020"],"gpt_icon":0},{"id":"2581050832","title":"上海医药：10月31日进行路演，中信建投、新华资产等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2581050832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581050832?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:33","pubTimestamp":1762421629,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年11月6日上海医药发布公告称公司于2025年10月31日进行路演，中信建投、新华资产、中邮保险、建信养老、其他34家机构、中信证券、国盛证券、中金公司、银河证券、兴业证券、天风证券、浙商证券、UBS参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600027597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","02607","601066","BK0020","BK0183","BK0188","601607","BK0175","BK0187","BK0028","BK0209","BK0196","BK0184","BK0099","BK1197","BK0097","BK0276"],"gpt_icon":0},{"id":"2581057846","title":"上海医药(601607.SH)：枸橼酸托法替布缓释片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2581057846","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581057846?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:16","pubTimestamp":1762420601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药中西制药有限公司(简称“上药中西”)的枸橼酸托法替布缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2025S03257)，该药品获得批准生产。枸橼酸托法替布缓释片用于治疗类风湿关节炎、银屑病关节炎和强直性脊柱炎，最早由Pfizer公司研发，于2016年在美国上市。2024年1月，上药中西就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入研发费用约人民币1,941.92万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0028","BK0188","BK0209","BK0196","BK1197","601607","BK0187","BK0020","BK0097","BK0175","BK0099","02607","BK0183","BK0184"],"gpt_icon":0},{"id":"2581844057","title":"上海医药(601607.SH)：替格瑞洛片获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2581844057","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581844057?lang=zh_cn&edition=full","pubTime":"2025-11-06 17:15","pubTimestamp":1762420500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属常州制药厂有限公司(简称“常州制药厂”)收到美国食品药品监督管理局(简称“美国FDA”)的通知，其关于替格瑞洛片的简略新药申请(“ANDA”，即美国仿制药申请)已获得最终批准上市。替格瑞洛片用于急性冠脉综合征患者，包括接受药物治疗和经皮冠状动脉介入治疗的患者，降低血栓性心血管事件的发生率。原研由AstraZeneca研发，于2011年在美国上市。2021年05月，常州制药厂就该药品向美国FDA提出ANDA申请，并于近日获得最终批准上市。截至本公告日，公司针对该药品已投入研发费用约人民币967.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366090.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0183","BK0020","601607","BK0175","BK0188","BK0012","BK0196","BK0209","BK0184","BK0187","BK0099","BK1197","BK0028","BK0097"],"gpt_icon":0},{"id":"2580326783","title":"瑞银：升上海医药(02607)目标价至15港元 评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2580326783","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580326783?lang=zh_cn&edition=full","pubTime":"2025-11-03 16:31","pubTimestamp":1762158660,"startTime":"0","endTime":"0","summary":"估值基准向前滚动一年后，H股目标价由14.5港元升至15港元，评级“买入”。上海医药首三季营业收入2,151亿元人民币(下同)，同比增长2.6%;归母净利润51.5亿元，同比增长27%;经常性归母净利润为27亿元，同比降26.8%。该行预计重点中药产品与合并上海和黄医药将推动2025年工业收入正增长，商业板块增速应持续领先行业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601607","02607"],"gpt_icon":0},{"id":"2580790744","title":"每周股票复盘：上海医药（601607）Q3净利降38.13%，拟每10股派1.2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580790744","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580790744?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:50","pubTimestamp":1762030218,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，上海医药报收于17.94元，较上周的18.28元下跌1.86%。本周，上海医药10月30日盘中最高价报18.42元。公司公告汇总上海医药集团股份有限公司拟实施2025年半年度利润分配方案，以截至2025年6月30日总股本3,708,361,809股为基数，向全体股东每10股派发现金红利1.20元（含税），合计拟派发现金红利总额为445,003,417.08元（含税），占2025年半年度合并归属于上市公司股东净利润的9.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601607","BK0012","BK0097","BK0028","BK0187","BK0188","BK0099","BK1197","BK0183","BK0184","BK0196","BK0020","BK0209","02607","BK0175"],"gpt_icon":0},{"id":"2579482285","title":"港股异动 | 上海医药(02607)跌超5% 计提资产减值准备增加 三季度纯利同比下降38.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579482285","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579482285?lang=zh_cn&edition=full","pubTime":"2025-10-31 11:25","pubTimestamp":1761881154,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，上海医药(02607)跌超5%，截至发稿，跌5.11%，报11.71港元，成交额1.09亿港元。消息面上，上海医药发布2025年第三季度报告，2025年1-9月，公司实现营业收入2150.72亿元(币种为人民币，下同)，同比增长2.60%；公司实现归属于上市公司股东的净利润51.47亿元，同比上升26.96%。单看第三季度，该公司实现营业收入734.79亿元，同比增长4.65%；归母净利润6.88亿元，同比下降38.13%，主要由于本季度内计提的资产减值准备增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0209","BK0175","BK0020","02607","BK0099","BK0188","BK0187","BK0184","BK0196","601607","BK0097","BK0183","BK0012","BK0028","BK1197"],"gpt_icon":0},{"id":"2579491521","title":"图解上海医药三季报：第三季度单季净利润同比下降38.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579491521","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579491521?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:14","pubTimestamp":1761826492,"startTime":"0","endTime":"0","summary":"证券之星消息，上海医药2025年三季报显示，前三季度公司主营收入2150.72亿元，同比上升2.6%；归母净利润51.47亿元，同比上升26.96%；扣非净利润26.99亿元，同比下降26.79%；其中2025年第三季度，公司单季度主营收入734.79亿元，同比上升4.65%；单季度归母净利润6.88亿元，同比下降38.13%；单季度扣非净利润5.99亿元，同比下降38.94%；负债率62.14%，投资收益33.7亿元，财务费用11.15亿元，毛利率10.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","601607"],"gpt_icon":0},{"id":"2579345141","title":"上海医药拟每10股派发现金红利1.2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579345141","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579345141?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:51","pubTimestamp":1761825060,"startTime":"0","endTime":"0","summary":"10月30日，上海医药（601607/02607）发布公告，公司拟向全体股东每10股派发现金红利1.2元（含税），预计总派发金额为4.45亿元，占归母净利润的9.98%。 2025年前三季度，上海医药实现收入2150.72亿元，归母净利润51.47亿元。（文章来源：财中社）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-10-30/doc-infvsqmk7741153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0099","BK0028","BK0012","BK0097","BK0196","BK0209","BK1197","BK0184","601607","BK0188","BK0183","BK0187","BK0175","02607","BK0020"],"gpt_icon":0},{"id":"2578982036","title":"上海医药(601607.SH)：溴吡斯的明缓释片获得批准生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2578982036","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578982036?lang=zh_cn&edition=full","pubTime":"2025-10-28 15:36","pubTimestamp":1761636965,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，近日，公司下属上海上药中西制药有限公司(简称“上药中西”)的溴吡斯的明缓释片收到国家药品监督管理局颁发的《药品注册证书》(证书编号：2025S03175)，该药品获得批准生产。溴吡斯的明缓释片可用于治疗重症肌无力，最早由BAUSCH公司研发，于1959年在美国上市。2024年3月，上药中西就该药品向国家药监局提出注册上市申请，并获受理。截至公告日，公司针对该药品已投入的研发费用约人民币1,600.9万元。截至本公告日，中国境内溴吡斯的明缓释片暂无其他企业上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02607","BK0187","BK0099","BK0184","BK0012","BK0188","BK0028","BK0196","BK1197","BK0183","BK0020","BK0209","BK0175","601607","BK0097"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765028600079,"stockEarnings":[{"period":"1week","weight":0.0051},{"period":"1month","weight":0.0022},{"period":"3month","weight":-0.0235},{"period":"6month","weight":-0.0149},{"period":"1year","weight":-0.1447},{"period":"ytd","weight":-0.1345}],"compareEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":-0.0167},{"period":"3month","weight":0.0237},{"period":"6month","weight":0.1529},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1644}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海医药集团股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"0人","perCapita":"--","listingDate":"1994-03-24","address":"上海市浦东新区中国(上海)自由贸易试验区张江路92号","registeredCapital":"370836万元","survey":" 上海医药集团股份有限公司的主营业务是医药工业、医药商业。公司的主要产品是硫酸羟氯喹片、多糖铁复合物胶囊、注射用乌司他丁、胃复春胶囊、双歧杆菌三联活菌制剂。报告期内，公司再度入选《财富》世界500强和全球最具价值医药品牌榜25强，排名分别提升至第407位和第19位。","listedPrice":4.5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海医药,601607,上海医药股票,上海医药股票老虎,上海医药股票老虎国际,上海医药行情,上海医药股票行情,上海医药股价,上海医药股市,上海医药股票价格,上海医药股票交易,上海医药股票购买,上海医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海医药(601607)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海医药(601607)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}